This company listing is no longer active
Oxurion Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Belangrijke informatie
-2.4%
Groei van de winst
-1.2%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 17.0% |
Inkomstengroei | -29.8% |
Rendement op eigen vermogen | n/a |
Nettomarge | -2,584.9% |
Volgende winstupdate | 24 Mar 2023 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Oxurion geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
31 Dec 21 | 1 | -29 | 8 | 21 |
30 Sep 21 | 1 | -30 | 9 | 22 |
30 Jun 21 | 1 | -31 | 9 | 23 |
31 Mar 21 | 2 | -29 | 9 | 23 |
31 Dec 20 | 2 | -28 | 9 | 22 |
30 Sep 20 | 3 | -30 | 10 | 23 |
30 Jun 20 | 3 | -32 | 11 | 24 |
31 Mar 20 | 4 | -42 | 12 | 25 |
31 Dec 19 | 4 | -52 | 13 | 26 |
30 Sep 19 | 4 | -54 | 14 | 27 |
30 Jun 19 | 3 | -57 | 14 | 28 |
31 Mar 19 | 4 | -48 | 13 | 29 |
31 Dec 18 | 5 | -38 | 13 | 30 |
30 Sep 18 | 6 | -8 | 12 | 28 |
30 Jun 18 | 7 | 23 | 11 | 26 |
31 Mar 18 | 6 | 23 | 11 | 25 |
31 Dec 17 | 6 | 23 | 10 | 23 |
30 Sep 17 | 6 | -19 | 10 | 23 |
30 Jun 17 | 6 | -61 | 11 | 23 |
31 Mar 17 | 6 | -60 | 11 | 24 |
31 Dec 16 | 7 | -60 | 11 | 25 |
30 Sep 16 | 8 | -47 | 14 | 24 |
30 Jun 16 | 9 | -34 | 17 | 23 |
31 Mar 16 | 10 | -36 | 21 | 22 |
31 Dec 15 | 11 | -38 | 26 | 21 |
Kwaliteitswinsten: TBGN.F is currently unprofitable.
Groeiende winstmarge: TBGN.F is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: TBGN.F is unprofitable, and losses have increased over the past 5 years at a rate of 2.4% per year.
Versnelling van de groei: Unable to compare TBGN.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: TBGN.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (60.8%).
Rendement op eigen vermogen
Hoge ROE: TBGN.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.